A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population Journal Article


Authors: Antoniou, A. C.; Wang, X.; Fredericksen, Z. S.; McGuffog, L.; Tarrell, R.; Sinilnikova, O. M.; Healey, S.; Morrison, J.; Kartsonaki, C.; Lesnick, T.; Ghoussaini, M.; Barrowdale, D.; EMBRACE; Peock, S.; Cook, M.; Oliver, C.; Frost, D.; Eccles, D.; Evans, D. G.; Eeles, R.; Izatt, L.; Chu, C.; Douglas, F.; Paterson, J.; Stoppa-Lyonnet, D.; Houdayer, C.; Mazoyer, S.; Giraud, S.; Lasset, C.; Remenieras, A.; Caron, O.; Hardouin, A.; Berthet, P.; GEMO Study Collaborators; Hogervorst, F. B. L.; Rookus, M. A.; Jager, A.; Van Den Ouweland, A.; Hoogerbrugge, N.; van der Luijt, R. B.; Meijers-Heijboer, H.; Gomez García, E. B.; HEBON; Devilee, P.; Vreeswijk, M. P. G.; Lubinski, J.; Jakubowska, A.; Gronwald, J.; Huzarski, T.; Byrski, T.; Górski, B.; Cybulski, C.; Spurdle, A. B.; Holland, H.; Goldgar, D. E.; John, E. M.; Hopper, J. L.; Southey, M.; Buys, S. S.; Daly, M. B.; Terry, M. B.; Schmutzler, R. K.; Wappenschmidt, B.; Engel, C.; Meindl, A.; Preisler-Adams, S.; Arnold, N.; Niederacher, D.; Sutter, C.; Domchek, S. M.; Nathanson, K. L.; Rebbeck, T.; Blum, J. L.; Piedmonte, M.; Rodriguez, G. C.; Wakeley, K.; Boggess, J. F.; Basil, J.; Blank, S. V.; Friedman, E.; Kaufman, B.; Laitman, Y.; Milgrom, R.; Andrulis, I. L.; Glendon, G.; Ozcelik, H.; Kirchhoff, T.; Vijai, J.; Gaudet, M. M.; Altshuler, D.; Guiducci, C.; SWE-BRCA; Loman, N.; Harbst, K.; Rantala, J.; Ehrencrona, H.; Gerdes, A. M.; Thomassen, M.; Sunde, L.; Peterlongo, P.; Manoukian, S.; Bonanni, B.; Viel, A.; Radice, P.; Caldes, T.; de la Hoya, M.; Singer, C. F.; Fink-Retter, A.; Greene, M. H.; Mai, P. L.; Loud, J. T.; Guidugli, L.; Lindor, N. M.; Hansen, T. V. O.; Nielsen, F. C.; Blanco, I.; Lazaro, C.; Garber, J.; Ramus, S. J.; Gayther, S. A.; Phelan, C.; Narod, S.; Szabo, C. I.; MOD SQUAD; Benitez, J.; Osario, A.; Nevanlinna, H.; Heikkinen, T.; Caligo, M. A.; Beattie, M. S.; Hamann, U.; Godwin, A. K.; Montagna, M.; Casella, C.; Neuhausen, S. L.; Karlan, B. Y.; Tung, N.; Toland, A. E.; Weitzel, J.; Olopade, O.; Simard, J.; Soucy, P.; Rubinstein, W. S.; Arason, A.; Rennert, G.; Martin, N. G.; Montgomery, G. W.; Chang-Claude, J.; Flesch-Janys, D.; Brauch, H.; GENICA; Severi, G.; Baglietto, L.; Cox, A.; Cross, S. S.; Miron, P.; Gerty, S. M.; Tapper, W.; Yannoukakos, D.; Fountzilas, G.; Fasching, P. A.; Beckmann, M. W.; dos Santos Silva, I.; Peto, J.; Lambrechts, D.; Paridaens, R.; Rudiger, T.; Forsti, A.; Winqvist, R.; Pylkas, K.; Diasio, R. B.; Lee, A. M.; Eckel-Passow, J.; Vachon, C.; Blows, F.; Driver, K.; Dunning, A.; Pharoah, P. D. P.; Offit, K.; Pankratz, V. S.; Hakonarson, H.; Chenevix-Trench, G.; Easton, D. F.
Article Title: A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population
Abstract: Germline BRCA1 mutations predispose to breast cancer. To identify genetic modifiers of this risk, we performed a genome-wide association study in 1,193 individuals with BRCA1 mutations who were diagnosed with invasive breast cancer under age 40 and 1,190 BRCA1 carriers without breast cancer diagnosis over age 35. We took forward 96 SNPs for replication in another 5,986 BRCA1 carriers (2,974 individuals with breast cancer and 3,012 unaffected individuals). Five SNPs on 19p13 were associated with breast cancer risk (P trend = 2.3 × 10 9 to P trend = 3.9 × 10 7), two of which showed independent associations (rs8170, hazard ratio (HR) = 1.26, 95% CI 1.17-1.35; rs2363956 HR = 0.84, 95% CI 0.80-0.89). Genotyping these SNPs in 6,800 population-based breast cancer cases and 6,613 controls identified a similar association with estrogen receptor-negative breast cancer (rs2363956 per-allele odds ratio (OR) = 0.83, 95% CI 0.75-0.92, P trend = 0.0003) and an association with estrogen receptor-positive disease in the opposite direction (OR = 1.07, 95% CI 1.01-1.14, P trend = 0.016). The five SNPs were also associated with triple-negative breast cancer in a separate study of 2,301 triple-negative cases and 3,949 controls (Ptrend = 1 × 10 7 to P trend = 8 × 10 5; rs2363956 per-allele OR = 0.80, 95% CI 0.74-0.87, P trend = 1.1 × 10 7). © 2010 Nature America, Inc. All rights reserved.
Keywords: adult; controlled study; gene mutation; major clinical study; single nucleotide polymorphism; mutation; case-control studies; polymorphism, single nucleotide; clinical trial; cancer risk; cancer diagnosis; prospective study; genetic analysis; allele; genetic predisposition to disease; breast cancer; mastectomy; prevalence; cohort analysis; gene locus; genetic association; genetic variability; genotype; gene frequency; breast neoplasms; brca1 protein; heterozygote; risk factor; cancer invasion; multicenter study; chromosomes, human, pair 19; receptor, erbb-2; receptors, estrogen; receptors, progesterone; hazard ratio; estrogen receptor; hormone receptor; population based case control study; chromosome 19p; chromosome 19p13; gene replacement therapy
Journal Title: Nature Genetics
Volume: 42
Issue: 10
ISSN: 1061-4036
Publisher: Nature Publishing Group  
Date Published: 2010-10-01
Start Page: 885
End Page: 892
Language: English
DOI: 10.1038/ng.669
PUBMED: 20852631
PROVIDER: scopus
PMCID: PMC3130795
DOI/URL:
Notes: --- - "Cited By (since 1996): 6" - "Export Date: 20 April 2011" - "CODEN: NGENE" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Kenneth Offit
    790 Offit
  2. Vijai Joseph
    212 Joseph